A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Sponsor
Hoffmann-La Roche
Study ID
NCT01705730
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • tocilizumab — DRUG
    Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.

Study Details

This observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in monotherapy in routine clinical practice in participants with rheumatoid arthritis. Eligible participants initiated on RoActemra/Actemra treatment according to the licensed label will be followed for 6 months.

Key Dates

First listed
Oct 12, 2012
Start date
Jul 31, 2012
Status verified
Aug 2018
Primary completion
Dec 12, 2014
Completion
Dec 12, 2014

Study Design

Enrollment
71 participants (actual)

Arms

  • Arm: Tocilizumab
    Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.

Primary Outcome Measure

Percentage of Participants on Tocilizumab Treatment at Month 6 After Treatment Initiation [ Time Frame: Month 6 after treatment initiation ]

Find similar trials

Nationwide
Rheumatoid arthritis trialsRheumatology trialsAutoimmune disease trialsMusculoskeletal disorders trials

Related Studies